Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Keros Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from 14 brokerages, with an average price target of $30.00.
• The company's recent quarterly earnings report showed an EPS of ($0.76), beating expectations of ($1.14), but with revenue significantly below estimates at $0.02 million.
• Institutional investors hold 71.56% of Keros Therapeutics stock, indicating strong interest from major financial entities.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $30.00.

Several equities analysts have recently weighed in on the company. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank lowered their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Finally, HC Wainwright lowered their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th.

Keros Therapeutics Stock Up 2.6%

Keros Therapeutics stock opened at $15.56 on Monday. The company has a market capitalization of $632.05 million, a P/E ratio of 50.20, a PEG ratio of 1.91 and a beta of 1.33. The stock's 50 day moving average is $14.04 and its 200 day moving average is $13.01. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm's quarterly revenue was up 49002.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.25) EPS. As a group, equities analysts expect that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP increased its stake in shares of Keros Therapeutics by 226.1% in the 4th quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock worth $533,000 after purchasing an additional 23,342 shares in the last quarter. Darwin Global Management Ltd. increased its stake in shares of Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after purchasing an additional 163,403 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Keros Therapeutics in the 4th quarter worth $730,000. Barclays PLC increased its stake in shares of Keros Therapeutics by 79.2% in the 4th quarter. Barclays PLC now owns 107,542 shares of the company's stock worth $1,703,000 after purchasing an additional 47,528 shares in the last quarter. Finally, Tejara Capital Ltd purchased a new stake in shares of Keros Therapeutics in the 1st quarter worth $410,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.